Science 37 Holdings (Science 37 Holdings) Operating Income : $-60.22 Mil (TTM As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Science 37 Holdings Operating Income?

Science 37 Holdings's Operating Income for the three months ended in Sep. 2023 was $-8.99 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2023 was $-60.22 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Science 37 Holdings's Operating Income for the three months ended in Sep. 2023 was $-8.99 Mil. Science 37 Holdings's Revenue for the three months ended in Sep. 2023 was $14.89 Mil. Therefore, Science 37 Holdings's Operating Margin % for the quarter that ended in Sep. 2023 was -60.39%.

Science 37 Holdings's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Science 37 Holdings's annualized ROC % for the quarter that ended in Sep. 2023 was -325.29%. Science 37 Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -10,454.65%.

Science 37 Holdings Operating Income Historical Data

The historical data trend for Science 37 Holdings's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Science 37 Holdings Operating Income Chart

Science 37 Holdings Annual Data

Trend

Jun20

Jun21

Dec22

Operating Income

-0.59

-105.33

Science 37 Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Operating Income	Get a 7-Day Free Trial									-25.26	-22.16	-17.72	-11.35	-8.99

Science 37 Holdings Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-60.22 Mil.

Science 37 Holdings (NAS:SNCE) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Science 37 Holdings's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

	ROC % (Q: Sep. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Sep. 2023 ))	/ count )
=	-35.964 * ( 1 - -0.01% )	/	( (12.382	+	9.732)	/ 2 )
=	-35.9675964	/	11.057
=	-325.29 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	86.956	-	9.571	-	( 65.003	-	max(0, 18.797	-	86.756	+	65.003	))
=	12.382

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	75.727	-	9.588	-	( 56.407	-	max(0, 18.104	-	75.541	+	56.407	))
=	9.732

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Science 37 Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Sep. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-35.964	/	( ( (0 + max(0.68799999999999, 0))	+	(0 + max(-0.83299999999999, 0)) )	/	2 )
=	-35.964	/	( ( 0.68799999999999	+	0 )	/	2 )
=	-35.964	/	0.344
=	-10,454.65 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(11.928	+	0	+	6.921)	-	(9.571	+	2.84	+	5.75)
=	0.68799999999999

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(10.194	+	0	+	6.543)	-	(9.588	+	3.084	+	4.898)
=	-0.83299999999999

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Science 37 Holdings's Operating Margin % for the quarter that ended in Sep. 2023 is calculated as:

Operating Margin %	=	Operating Income (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-8.991	/	14.887
	=	-60.39 %

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Science 37 Holdings Operating Income Related Terms

Thank you for viewing the detailed overview of Science 37 Holdings's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Science 37 Holdings (Science 37 Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Science 37 Holdings Inc (NAS:SNCE) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

800 Park Offices Drive, Suite 3606, Research Triangle Park, Durham, NC, USA, 27709

Website

https://www.science37.com

Science 37 Holdings Inc is engaged in the development of new and innovative treatments that impact patient lives. It enables universal access to patients and providers for clinical trials. Its Operating System is fused with networks of telemedicine investigators, mobile nurses, remote coordinators, patient communities and connected devices.

Executives

Troy Bryenton	officer: Chief Technology Officer	800 PARK OFFICES DRIVE, SUITE 3606, RESEARCH TRIANGLE PARK NC 27709
Christine A Pellizzari	officer: Chief Legal Officer	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Autenried Paul Von	director	BRISTOL-MYERS SQUIBB COMPANY, 100 NASSAU PARK BOULEVARD, PRINCETON NJ 08543
Michael Shipton	officer: Chief Commercial Officer	800 PARK OFFICES DRIVE SUITE 3606, RESEARCH TRIANGLE PARK NC 27709
Adam Goulburn	director	C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Thermo Fisher Scientific Powder Us Holdings Corp.	10 percent owner	168 THIRD AVENUE, WALTHAM MA 02451
Thermo Fisher Scientific Inc.	10 percent owner	168 THIRD AVENUE, WALTHAM MA 02451
Neil Tiwari	director	C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Darcy Forman	officer: Chief Delivery Officer	C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
David Coman	director, officer: Chief Executive Officer	C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Jonathan Cotliar	officer: Chief Medical Officer	C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Steven Geffon	officer: Chief Commercial Officer	C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
De Silva Bhooshitha B.	director	PPD, INC., 929 NORTH FRONT STREET, WILMINGTON NC 28401
Mike Zaranek	officer: Chief Financial Officer	C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Ppd, Inc.	10 percent owner	929 NORTH FRONT STREET, WILMINGTON NC 28401-3331